[
    {
        "oncogenic": "Likely Oncogenic",
        "drugDescription": "Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",
        "cancerTypes": [
            {
                "id": 876,
                "subtype": "",
                "code": "",
                "color": "Gainsboro",
                "mainType": "Non-Small Cell Lung Cancer",
                "level": 0,
                "tissue": "Lung",
                "tumorForm": "SOLID"
            }
        ],
        "excludedCancerTypes": [],
        "variant": {
            "gene": {
                "entrezGeneId": 6098,
                "hugoSymbol": "ROS1",
                "grch37Isoform": "ENST00000368508",
                "grch37RefSeq": "NM_002944.2",
                "grch38Isoform": "ENST00000368508",
                "grch38RefSeq": "NM_002944.2",
                "geneAliases": [
                    "MCF3",
                    "ROS",
                    "c-ros-1"
                ],
                "genesets": [],
                "geneType": "ONCOGENE"
            },
            "consequence": {
                "term": "NA",
                "isGenerallyTruncating": false,
                "description": "NA"
            },
            "alteration": "Fusions",
            "name": "Fusions",
            "refResidues": null,
            "proteinStart": -1,
            "proteinEnd": 100000,
            "variantResidues": null,
            "referenceGenomes": [
                "GRCh38",
                "GRCh37"
            ]
        },
        "level": "2",
        "fdaLevel": "Fda2",
        "drug": [
            "Ceritinib"
        ],
        "drugPmids": [
            "28520527"
        ],
        "drugAbstracts": []
    },
    {
        "oncogenic": "Likely Oncogenic",
        "drugDescription": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",
        "cancerTypes": [
            {
                "id": 876,
                "subtype": "",
                "code": "",
                "color": "Gainsboro",
                "mainType": "Non-Small Cell Lung Cancer",
                "level": 0,
                "tissue": "Lung",
                "tumorForm": "SOLID"
            }
        ],
        "excludedCancerTypes": [],
        "variant": {
            "gene": {
                "entrezGeneId": 6098,
                "hugoSymbol": "ROS1",
                "grch37Isoform": "ENST00000368508",
                "grch37RefSeq": "NM_002944.2",
                "grch38Isoform": "ENST00000368508",
                "grch38RefSeq": "NM_002944.2",
                "geneAliases": [
                    "MCF3",
                    "ROS",
                    "c-ros-1"
                ],
                "genesets": [],
                "geneType": "ONCOGENE"
            },
            "consequence": {
                "term": "NA",
                "isGenerallyTruncating": false,
                "description": "NA"
            },
            "alteration": "Fusions",
            "name": "Fusions",
            "refResidues": null,
            "proteinStart": -1,
            "proteinEnd": 100000,
            "variantResidues": null,
            "referenceGenomes": [
                "GRCh38",
                "GRCh37"
            ]
        },
        "level": "1",
        "fdaLevel": "Fda2",
        "drug": [
            "Crizotinib"
        ],
        "drugPmids": [
            "30980071",
            "25264305",
            "29596029"
        ],
        "drugAbstracts": []
    },
    {
        "oncogenic": "Likely Oncogenic",
        "drugDescription": "Repotrectinib is an orally bioavailable tyrosine kinase inhibitor that targets ROS1. In the Phase I/II TRIDENT-1 study of repotrectinib in 171 patients with ROS1-fusion-positive non-small lung cancer (NSCLC), an overall objective response rate of 79% was found in patients who had not previously received a ROS1 tyrosine kinase inhibitor treatment. For patients previously treated with a ROS1 tyrosine kinase inhibitor, overall response rates were 38% if the patient did not previously receive chemotherapy, 42% if the patient did previously receive chemotherapy and 28% if the patient previously received two different ROS1 tyrosine kinase inhibitors (Abstract: Cho et al. Abstract# 2LBA, EJC 2022. https://www.ejcancer.com/article/S0959-8049(22)00812-7/fulltext).",
        "cancerTypes": [
            {
                "id": 876,
                "subtype": "",
                "code": "",
                "color": "Gainsboro",
                "mainType": "Non-Small Cell Lung Cancer",
                "level": 0,
                "tissue": "Lung",
                "tumorForm": "SOLID"
            }
        ],
        "excludedCancerTypes": [],
        "variant": {
            "gene": {
                "entrezGeneId": 6098,
                "hugoSymbol": "ROS1",
                "grch37Isoform": "ENST00000368508",
                "grch37RefSeq": "NM_002944.2",
                "grch38Isoform": "ENST00000368508",
                "grch38RefSeq": "NM_002944.2",
                "geneAliases": [
                    "MCF3",
                    "ROS",
                    "c-ros-1"
                ],
                "genesets": [],
                "geneType": "ONCOGENE"
            },
            "consequence": {
                "term": "NA",
                "isGenerallyTruncating": false,
                "description": "NA"
            },
            "alteration": "Fusions",
            "name": "Fusions",
            "refResidues": null,
            "proteinStart": -1,
            "proteinEnd": 100000,
            "variantResidues": null,
            "referenceGenomes": [
                "GRCh38",
                "GRCh37"
            ]
        },
        "level": "3A",
        "fdaLevel": "Fda3",
        "drug": [
            "Repotrectinib"
        ],
        "drugPmids": [],
        "drugAbstracts": [
            {
                "link": "https://www.ejcancer.com/article/S0959-8049(22",
                "abstract": "Cho et al. Abstract# 2LBA, EJC 2022"
            }
        ]
    },
    {
        "oncogenic": "Likely Oncogenic",
        "drugDescription": "Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",
        "cancerTypes": [
            {
                "id": 876,
                "subtype": "",
                "code": "",
                "color": "Gainsboro",
                "mainType": "Non-Small Cell Lung Cancer",
                "level": 0,
                "tissue": "Lung",
                "tumorForm": "SOLID"
            }
        ],
        "excludedCancerTypes": [],
        "variant": {
            "gene": {
                "entrezGeneId": 6098,
                "hugoSymbol": "ROS1",
                "grch37Isoform": "ENST00000368508",
                "grch37RefSeq": "NM_002944.2",
                "grch38Isoform": "ENST00000368508",
                "grch38RefSeq": "NM_002944.2",
                "geneAliases": [
                    "MCF3",
                    "ROS",
                    "c-ros-1"
                ],
                "genesets": [],
                "geneType": "ONCOGENE"
            },
            "consequence": {
                "term": "NA",
                "isGenerallyTruncating": false,
                "description": "NA"
            },
            "alteration": "Fusions",
            "name": "Fusions",
            "refResidues": null,
            "proteinStart": -1,
            "proteinEnd": 100000,
            "variantResidues": null,
            "referenceGenomes": [
                "GRCh38",
                "GRCh37"
            ]
        },
        "level": "2",
        "fdaLevel": "Fda2",
        "drug": [
            "Lorlatinib"
        ],
        "drugPmids": [
            "31669155"
        ],
        "drugAbstracts": []
    },
    {
        "oncogenic": "Likely Oncogenic",
        "drugDescription": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",
        "cancerTypes": [
            {
                "id": 876,
                "subtype": "",
                "code": "",
                "color": "Gainsboro",
                "mainType": "Non-Small Cell Lung Cancer",
                "level": 0,
                "tissue": "Lung",
                "tumorForm": "SOLID"
            }
        ],
        "excludedCancerTypes": [],
        "variant": {
            "gene": {
                "entrezGeneId": 6098,
                "hugoSymbol": "ROS1",
                "grch37Isoform": "ENST00000368508",
                "grch37RefSeq": "NM_002944.2",
                "grch38Isoform": "ENST00000368508",
                "grch38RefSeq": "NM_002944.2",
                "geneAliases": [
                    "MCF3",
                    "ROS",
                    "c-ros-1"
                ],
                "genesets": [],
                "geneType": "ONCOGENE"
            },
            "consequence": {
                "term": "NA",
                "isGenerallyTruncating": false,
                "description": "NA"
            },
            "alteration": "Fusions",
            "name": "Fusions",
            "refResidues": null,
            "proteinStart": -1,
            "proteinEnd": 100000,
            "variantResidues": null,
            "referenceGenomes": [
                "GRCh38",
                "GRCh37"
            ]
        },
        "level": "1",
        "fdaLevel": "Fda2",
        "drug": [
            "Entrectinib"
        ],
        "drugPmids": [
            "28183697"
        ],
        "drugAbstracts": [
            {
                "link": "https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397",
                "abstract": "Braud et al. Abstract# 64P, ESMO 2019"
            },
            {
                "link": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060",
                "abstract": "Drilon et al. Abstract# CT060, AACR 2017"
            }
        ]
    }
]